Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity
Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center)
Summary
This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single ascending dose of IBI3032 in healthy participants and multiple ascending doses of IBI3032 in participants with overweight or obesity. It consists of 2 parts: Part A is a single ascending dose (SAD) study in healthy participants, and Part B is a multiple ascending dose (MAD) study in participants with overweight or obesity during the 4-week treatment period.
Official title: A Phase 1 Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032 After a Single Ascending Dose in Healthy Participants and After Multiple Ascending Doses in Participants With Overweight or Obesity
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
104
Start Date
2025-09-04
Completion Date
2026-09-30
Last Updated
2026-04-08
Healthy Volunteers
Yes
Interventions
Placebo
Single dose placebo IBI3032 administered orally
IBI3032 tablets
Single dose of IBI3032 administered orally
Locations (1)
Zhongshan Hospital affiliated to Fudan University
Shanghai, Shanghai Municipality, China